Rimtuzalcap API Manufacturers
compare suppliers & get competitive offers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Rimtuzalcap API 2167246-24-2?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Rimtuzalcap. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Rimtuzalcap
- Synonyms:
- N-(4,4-difluorocyclohexyl)-2-(3-methyl-1H-pyrazol-1-yl)-6-morpholinopyrimidin-4-amine , Rimtuzalcap
- Cas Number:
- 2167246-24-2
- DrugBank number:
- DB16733
- Unique Ingredient Identifier:
- USO2D5J77R
General Description:
Rimtuzalcap, identified by CAS number 2167246-24-2, is a notable compound with significant therapeutic applications. Rimtuzalcap is a novel modulator of small-conductance calcium-activated potassium channels that is under investigation for the treatment of essential tremor.
Pharmacodynamics:
Rimtuzalcap exerts its therapeutic effects through: Rimtuzalcap is thought to decrease the firing of neurons in the olivo-cerebellar network which are theorized to contribute to the dysfunction of oscillatory neuronal input to the motor cortex that results in the presentation of motor tremors in the typical 4-12 Hz band associated with essential tremor. Inhibition of this dysfunctional firing may provide benefit to patients with essential tremor. The drug's ability to modulate various physiological processes underscores its efficacy in treating specific conditions.
Mechanism of Action:
Rimtuzalcap functions by: Rimtuzalcap is a positive allosteric modulator of small-conductance calcium-activated K+ channels (SK channels). It is thought to exert its activity on essential tremor through increasing SK channel activity in the Purkinje cells of the cerebellar cortex resulting in hyperpolarization and consequently, a slower firing rate. These Purkinje cells have a glutamatergic excitatory input to deep cerebellar neurons in the dentate nucleus which themselves exert the same input on the ventral intermediate nucleus in the thalamocortical system. From there the ventral intermediate nucleus exerts excitatory input to the motor cortex, producing an effect on motor function. It is the decrease in the activity of this pathway through targeting Purkinje cell firing rate that is thought to have a beneficial impact on essential tremor. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Rimtuzalcap is a type of Intermediates
Pharmaceutical intermediates are a crucial category within the API (Active Pharmaceutical Ingredient) industry. These chemical compounds play a vital role in the synthesis of APIs, serving as building blocks or precursor molecules in the manufacturing process. Pharmaceutical intermediates are designed to undergo specific chemical transformations, enabling the production of targeted APIs with desired properties.
These intermediates are typically produced through complex organic synthesis, involving various chemical reactions and purification steps. They are carefully developed and optimized to ensure high purity, stability, and safety, meeting stringent regulatory requirements for pharmaceutical use.
Pharmaceutical intermediates offer several advantages in API production. Firstly, they enable the efficient and cost-effective synthesis of APIs by providing a well-defined starting material. This reduces the need for expensive or hard-to-obtain raw materials, streamlining the overall manufacturing process. Secondly, intermediates allow for fine-tuning of the chemical reactions, optimizing the yield and quality of the final API. This control over the synthesis process enhances the consistency and reproducibility of pharmaceutical manufacturing.
Moreover, pharmaceutical intermediates facilitate the development of new APIs and drug formulations. By modifying the structure or functional groups of the intermediate molecules, researchers can explore different chemical pathways and create novel compounds with improved therapeutic efficacy, reduced side effects, or enhanced bioavailability.
In summary, pharmaceutical intermediates are essential components in API synthesis, enabling efficient and controlled production of pharmaceutical compounds. Their versatility and role in driving innovation make them indispensable in the pharmaceutical industry.
